Your current location:
Disease Models

Chronic Heart Failure

2018-08-20
19111
Kunming, China, August 20, 2018

Chronic heart failure (CHF) affects 26 million people worldwide and it increases with aging and acute cardiovascular events. Current therapies for the reduced ejection fraction (HFrEF) are inadequate and almost no effect to preserve ejection fraction (HFpEF). Rodent models of heart failure have been widely used for drug discovery and significantly advanced the understanding of the mechanisms. Cynomolgus monkeys with metabolic dysfunctions are ideal models to verify these findings prior to the trial in humans because the monkey species are much closer to patients and can spontaneously progress to CHF (Fig 1).


CHF 1.jpg


KBI has screened over 1000 monkeys fed HFD for two years or longer with severe metabolic syndrome by echocardiography. About 38% of these monkeys were found to have different extents of systolic or diastolic dysfunction (Fig 2, 3, 4).

CHF 2.jpg


CHF 3.jpg


CHF 4.jpg


N-terminal pro-brain natriuretic peptide (NT-proBNP) is a specific biomarker used for the assessment of CHF progression and treatment responses in patients. As shown in Fig 5, NT-proBNP is significantly elevated in the CHF monkeys and it allows us to assess efficacy and toxicity of test drugs.


CHF 5.jpg


MRI T1 mapping for determination of extracellular matrix volume (ECV) as a surrogate for the interstitial cardiac fibrosis is a diagnostic tool for HF patients, especially those with HFpEF. KBI has validated this non-invasive technique in the HFpEF monkeys (Fig 6).


CHF 6.jpg

 

Contact us if you need more information.

Copyright © 2022 Kunming Biomed International Ltd. All Rights Reserved     |Privacy Policy|Terms of Use|
4571 Boda Road, Chenggong, Kunming, Yunnan, 650500, China